{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:33:56Z","timestamp":1794004436356,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.therap.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:48:23Z","timestamp":1698792503000},"page":"161-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Drug-induced cardiac toxicity and adverse drug reactions, a narrative review"],"prefix":"10.1016","volume":"79","author":[{"given":"Alexandre","family":"Destere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Lavrut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2023.10.008_bib0385","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.therap.2023.10.008_bib0390","doi-asserted-by":"crossref","first-page":"815151","DOI":"10.3389\/fphar.2021.815151","article-title":"Characteristics and spectrum of cardiotoxicity induced by various antipsychotics: a real-world study from 2015 to 2020 based on FAERS","volume":"12","author":"He","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2023.10.008_bib0395","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pds.1424","article-title":"Cardiovascular risks of atypical antipsychotic drug treatment","volume":"16","author":"Drici","year":"2007","journal-title":"Pharmacoepidem Drug Saf"},{"key":"10.1016\/j.therap.2023.10.008_bib0400","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/00498254.2015.1046975","article-title":"Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect","volume":"46","author":"Salimi","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.therap.2023.10.008_bib0405","doi-asserted-by":"crossref","first-page":"1117254","DOI":"10.3389\/fcvm.2023.1117254","article-title":"Administration of macrolide antibiotics increases cardiovascular risk","volume":"10","author":"Wu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0410","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.1016\/j.xcrm.2021.100216","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0415","doi-asserted-by":"crossref","first-page":"798189","DOI":"10.3389\/fphar.2021.798189","article-title":"Editorial: recent advances in cardiotoxicity testing","volume":"12","author":"Mohamed","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2023.10.008_bib0420","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMe078117","article-title":"Rosiglitazone and cardiotoxicity\u00a0\u2014\u00a0Weighing the evidence","volume":"357","author":"Nathan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0425","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","article-title":"Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets\u00a0\u2013\u00a01960 to 1999","volume":"35","author":"Fung","year":"2001","journal-title":"Drug Information J"},{"key":"10.1016\/j.therap.2023.10.008_bib0430","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hlc.2021.03.273","article-title":"Mackay heart failure study: examining the root causes, compliance with guideline-based therapy and prognosis","volume":"30","author":"Naing","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.therap.2023.10.008_bib0435","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/jcm11030784","article-title":"Cause of death in heart failure based on etiology: long-term cohort study of all-cause and cardiovascular mortality","volume":"11","author":"Spitaleri","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0440","first-page":"e1144","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue","volume":"9","author":"Varga","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.therap.2023.10.008_bib0445","doi-asserted-by":"crossref","first-page":"847012","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0450","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11523-009-0112-2","article-title":"Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?","volume":"4","author":"De Azambuja","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.therap.2023.10.008_bib0455","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.therap.2023.10.008_bib0460","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cts.12883","article-title":"Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic","volume":"14","author":"Romani","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.therap.2023.10.008_bib0465","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3892\/mco.2016.800","article-title":"Cardiotoxicity associated with targeted cancer therapies","volume":"4","author":"Chen","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.therap.2023.10.008_bib0470","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","article-title":"\u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers","volume":"75","author":"G\u00e9rard","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2023.10.008_bib0475","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpt.2617","article-title":"Real-world data on the risk of ventricular arrhythmias with sulfonamides","volume":"112","author":"G\u00e9rard","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.10.008_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.respe.2016.06.335","article-title":"Anti\u00e9m\u00e9tiques et effets cardiaques potentiellement li\u00e9s \u00e0 un allongement de l\u2019intervalle QT\u00a0: analyse cas\/non-cas dans la base nationale de pharmacovigilance","volume":"65","author":"Rochoy","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.therap.2023.10.008_bib0485","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor\u2013associated QTc prolongation","volume":"75","author":"Beach","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2023.10.008_bib0490","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s00213-017-4685-7","article-title":"A comparative study of QT prolongation with serotonin reuptake inhibitors","volume":"234","author":"Ojero-Senard","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2023.10.008_bib0495","unstructured":"Crediblemeds 2023. https:\/\/crediblemeds.org\/ [Accessed 7 September 2023]."},{"key":"10.1016\/j.therap.2023.10.008_bib0500","doi-asserted-by":"crossref","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.10.008_bib0505","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000086459","article-title":"Selective COX-2 inhibitors and risk of myocardial infarction","volume":"42","author":"Kr\u00f6tz","year":"2005","journal-title":"J Vasc Res"},{"key":"10.1016\/j.therap.2023.10.008_bib0510","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2023.10.008_bib0515","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.1144","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue","author":"Varga","year":"2017","journal-title":"Cureus [Internet]"},{"key":"10.1016\/j.therap.2023.10.008_bib0520","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.therap.2023.10.008_bib0525","doi-asserted-by":"crossref","first-page":"227","DOI":"10.31083\/j.rcm2307227","article-title":"Mechanisms of myocardial ischemia in cancer patients: a state-of-the-art review of obstructive versus non-obstructive causes","volume":"23","author":"Balanescu","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0530","doi-asserted-by":"crossref","first-page":"962596","DOI":"10.3389\/fphar.2022.962596","article-title":"Cardiotoxicity associated with immune checkpoint inhibitors: current status and future challenges","volume":"13","author":"Gan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2023.10.008_bib0535","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0540","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.therap.2023.10.008_bib0545","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.therap.2023.10.008_bib0550","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/fcp.12102","article-title":"Are nilotinib-associated vascular adverse events an under-estimated problem?","volume":"29","author":"St\u00e8ve-Dumont","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.10.008_bib0555","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2023.10.008_bib0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2017.01.005","article-title":"Acute myocardial infarction from coronary vasospasm precipitated by pseudoephedrine and metoprolol use","volume":"33","author":"Meoli","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.therap.2023.10.008_bib0565","doi-asserted-by":"crossref","unstructured":"Pugliese A.M., Coppi E., Cherchi F., Pepeu G. Cardiovascular adverse effects of psychotropic drugs. In: Govoni S., Politi P., Vanoli E., editors. Brain and heart dynamics. Springer, Cham: Springer International Publishing; 2020. p. 707\u2013720. http:\/\/link.springer.com\/10.1007\/978-3-030-28008-645 [Accessed 7 September 2023].","DOI":"10.1007\/978-3-030-28008-6_45"},{"key":"10.1016\/j.therap.2023.10.008_bib0570","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00001648-199507000-00008","article-title":"Is the use of psychotropic drugs associated with increased risk of ischemic heart disease?","volume":"6","author":"Lapane","year":"1995","journal-title":"Epidemiology"},{"key":"10.1016\/j.therap.2023.10.008_bib0575","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0002-9343(99)00301-0","article-title":"Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents","volume":"108","author":"Cohen","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0580","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.amjmed.2004.06.027","article-title":"Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study","volume":"117","author":"Monster","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0585","doi-asserted-by":"crossref","first-page":"113744","DOI":"10.1016\/j.psychres.2021.113744","article-title":"Comparison of risk of cardiovascular disease related adverse events between selective serotonin reuptake inhibitor users and serotonin norepinephrine reuptake inhibitor users in Korean adult patients with depression: retrospective cohort study","volume":"298","author":"Park","year":"2021","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.therap.2023.10.008_bib0590","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/phar.2686","article-title":"Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression","volume":"42","author":"Desai","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.10.008_bib0595","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"G\u00e9rard","year":"2022","journal-title":"J Headache Pain"},{"key":"10.1016\/j.therap.2023.10.008_bib0600","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1177\/0333102419877169","article-title":"Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors\u00a0\u2013\u00a0important studies on human isolated arteries","volume":"39","author":"Messlinger","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.therap.2023.10.008_bib0605","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/phar.2706","article-title":"Myocardial infarction associated with erenumab: a case report","volume":"42","author":"Perino","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2023.10.008_bib0610","first-page":"561","article-title":"Incidence and management of clozapine-induced myocarditis in a large tertiary hospital","volume":"64","author":"Higgins","year":"2019","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.therap.2023.10.008_bib0615","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cpt.2499","article-title":"Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level","volume":"111","author":"Chouchana","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2023.10.008_bib0620","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pcad.2022.10.004","article-title":"Myocarditis associated with COVID-19 and its vaccines\u00a0\u2013\u00a0a systematic review","volume":"74","author":"Rout","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.therap.2023.10.008_bib0625","doi-asserted-by":"crossref","first-page":"517","DOI":"10.15585\/mmwr.mm7114e1","article-title":"Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination\u00a0\u2014\u00a0PCORnet, United States, January 2021\u2013January 2022","volume":"71","author":"Block","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.therap.2023.10.008_bib0630","doi-asserted-by":"crossref","first-page":"e000373","DOI":"10.1136\/bmjmed-2022-000373","article-title":"Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study","volume":"2","author":"Husby","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0635","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/acps.13398","article-title":"Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis","volume":"145","author":"Vickers","year":"2022","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.therap.2023.10.008_bib0640","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","article-title":"Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case\u2013control study","volume":"141","author":"Ronaldson","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.therap.2023.10.008_bib0645","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.therap.2023.10.008_bib0650","unstructured":"NSW health. Monitoring clozapine-induced myocarditis. 2022. https:\/\/www1.health.nsw.gov.au\/pds\/ActivePDSDocuments\/GL2022_011.pdf [Accessed 7 September 2023 (13 pp.)]."},{"key":"10.1016\/j.therap.2023.10.008_bib0655","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2125.2012.04252.x","article-title":"Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, \u2018Ecstasy\u2019): letter to the Editors","volume":"74","author":"Montastruc","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.10.008_bib0660","unstructured":"Ceron C., Goyal A., Makaryus A.N. Drug-induced valvular heart disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470183\/ [Accessed 7 September 2023]."},{"key":"10.1016\/j.therap.2023.10.008_bib0665","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2023.10.008_bib0670","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2006.00441.x","article-title":"Valvular heart disease in a patient taking benfluorex","volume":"20","author":"Noize","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2023.10.008_bib0675","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/pds.2044","article-title":"Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus","volume":"19","author":"Weill","year":"2010","journal-title":"Pharmacoepidem Drug Safe"},{"key":"10.1016\/j.therap.2023.10.008_bib0680","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2023.10.008_bib0685","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2020.10.028","article-title":"Spontaneous reported cardiotoxicity induced by lopinavir\/ritonavir in COVID-19. An alleged past-resolved problem","volume":"324","author":"Fresse","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.therap.2023.10.008_bib0690","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.therap.2023.10.008_bib0695","article-title":"Cardiac failure caused by the association of carboplatin and gemcitabine chemotherapy in a patient with metastatic urothelial cancer: a case report","volume":"05","author":"Tiong","year":"2015","journal-title":"J Clin Case Rep"},{"key":"10.1016\/j.therap.2023.10.008_bib0700","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.therap.2023.10.008_bib0705","doi-asserted-by":"crossref","first-page":"e19258","DOI":"10.1097\/MJT.0000000000000430","article-title":"Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma","volume":"23","author":"Roth","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.therap.2023.10.008_bib0710","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of Takotsubo-like syndrome","volume":"3","author":"Geisler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.therap.2023.10.008_bib0715","first-page":"1","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0720","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2023.10.008_bib0725","doi-asserted-by":"crossref","first-page":"295303","DOI":"10.1517\/14740338.2015.989210","article-title":"Cardiac risks associated with antibiotics: azithromycin and levofloxacin","volume":"14","author":"Lu","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.therap.2023.10.008_bib0730","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4236\/pp.2012.32028","article-title":"Ciprofloxacin cardiotoxicity and hepatotoxicity in humans and animals","volume":"3","author":"Adikwu","year":"2012","journal-title":"Pharmacol Pharm"},{"key":"10.1016\/j.therap.2023.10.008_bib0735","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.therap.2023.10.008_bib0740","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/157488612802715735","article-title":"Update on the cardiac safety of moxifloxacin","volume":"7","author":"Haverkamp","year":"2012","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.therap.2023.10.008_bib0745","doi-asserted-by":"crossref","first-page":"e2018069","DOI":"10.4084\/mjhid.2018.069","article-title":"Cardiac toxicity associated with HCV direct antiviral agents","volume":"10","author":"Ucciferri","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.therap.2023.10.008_bib0750","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/biomedicines10071573","article-title":"Saxagliptin cardiotoxicity in chronic heart failure: the role of DPP4 in the regulation of neuropeptide tone","volume":"10","author":"V\u00f6r\u00f6s","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.therap.2023.10.008_bib0755","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2214\/AJR.07.3421","article-title":"Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions","volume":"191","author":"Wang","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.therap.2023.10.008_bib0760","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595723001695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:58:43Z","timestamp":1711655923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595723001695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0040595723001695"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2023.10.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced cardiac toxicity and adverse drug reactions, a narrative review","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}